Sodium iodide-i-131 Pregnancy and Breastfeeding Warnings

Brand names: Hicon, Iodotope, i3odine Max

Sodium iodide-i-131 Pregnancy Warnings

Sodium iodide-I-131 has been assigned to pregnancy category X by the FDA. Sodium iodide-I-131 is contraindicated in women who are or may become pregnant. Sodium iodide-I-131 readily crosses the placenta. The fetal thyroid is able to accumulate I-131 until after about 10 to 12 weeks of gestation. Therapeutic doses of sodium iodide-I-131 administered near the end of the first trimester (12 weeks or beyond) usually result in partial or complete abolition of the fetal thyroid. Patients treated with sodium iodide-I-131 should be advised to delay conception for at least six months after treatment. Animal reproduction studies have not been conducted with sodium iodide-I-131.

See references

Sodium iodide-i-131 Breastfeeding Warnings

Sodium iodide-I-131 is concentrated in breast milk. Because exposure to radioactive iodine may result in damage to the nursing infants thyroid, including an increased risk of thyroid cancer, breast-feeding should be stopped until radioactivity is no longer present in breast milk.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer